⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700014 | 1.00 | — | — | |
| SCHEMBL5700375 | 0.82 | — | — | |
| SCHEMBL10237581 | 0.79 | — | — | |
| SCHEMBL29955436 | 0.78 | KMT2A (0.46) | — | |
| SCHEMBL2600757 | 0.78 | KMT2A (0.46) | — | |
| SCHEMBL19001356 | 0.77 | — | — | |
| SCHEMBL844320 | 0.73 | — | — | |
| SCHEMBL22513198 | 0.73 | — | — | |
| SCHEMBL1043574 | 0.73 | — | — | |
| SCHEMBL29952845 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230346779-A1 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116406259-A | Dosage form compositions comprising inhibitors of BTK and mutants thereof | 广州麓鹏制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-05-05 | — | — | US | disclosed |